Safety first with
Liver Safety+
Leverage the only platform that allows you to predict liver safety during discovery.
Every year, promising drug candidates move into clinical trials only to be flagged for potential drug-induced liver injury (DILI) risk. Millions of dollars and countless hours of research have been poured into therapies that end up shelved or dumped—but until now, there’s been no way to anticipate DILI risk earlier in the drug development process.
Liver Safety+ is the only platform that allows you to design and optimize drug compounds for efficacy—then rank order them by relative DILI risk while still in the discovery phase.
This package harnesses the industry-leading drug design and optimization capabilities of ADMET Predictor® and powerful DILIsym® technology to quickly generate drug candidates and insight into the likelihood of liver safety concerns. It allows you to make faster and more informed decisions about which compounds to prioritize for development.
While others must wait for the results of costly clinical trials, you can identify potential DILI hazards early in development and direct your time and resources to the compounds likeliest to achieve success.
Christina Battista
James J. Beaudoin
Michael Lawless
